We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PhotoMedex and Galderma to Co-Promote Actinic Keratosis Treatment
News

PhotoMedex and Galderma to Co-Promote Actinic Keratosis Treatment

PhotoMedex and Galderma to Co-Promote Actinic Keratosis Treatment
News

PhotoMedex and Galderma to Co-Promote Actinic Keratosis Treatment

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PhotoMedex and Galderma to Co-Promote Actinic Keratosis Treatment"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PhotoMedex and Galderma Laboratories, L.P. have entered into a co-promotion agreement for Galderma’s photodynamic therapy application for the treatment of actinic keratoses (AK).

Under the terms of the agreement, PhotoMedex’ sales force will promote Galderma’s drug Metvixia® (methyl aminolevulinate) Cream, 16.8% (“Metvixia”) and Galderma’s Aktilite® CL128 LED (light-emitting diode) lamp to healthcare professionals, including dermatologists, plastic surgeons and cosmetic surgeons throughout the United States. Galderma will provide marketing support and distribution. The three-year agreement begins in January; no financial terms have been disclosed.

Actinic keratoses are very common lesions that occur on sun-damaged skin and are widely considered to be a precursor to squamous cell carcinoma.

Metvixia is a topical porphyrin precursor used in photodynamic therapy. When applied to actinic keratosis lesions, Metvixia is selectively absorbed into precancerous cells causing a build-up of endogenous porphyrins. These endogenous porphyrins are illuminated with the Aktilite CL128 lamp emitting a narrow output spectrum of red light with a peak wavelength at 630 nm. Subsequently, a reaction occurs that results in the destruction of the precancerous cells.

According to Galderma, clinical trials in various countries with the Metvixia PDT system have shown comparable or better response rates than conventional treatments, such as cryotherapy or surgery.
Advertisement